Trial Profile
A Phase II Study of M6620 (VX-970) in Selected Solid Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Berzosertib (Primary)
- Indications Leiomyosarcoma; Osteosarcoma; Solid tumours
- Focus Therapeutic Use
- 07 Apr 2022 Status changed from active, no longer recruiting to completed.
- 02 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 11 Jan 2019 Status changed from not yet recruiting to recruiting.